{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:09:47Z","timestamp":1789200587563,"version":"build-2803163510"},"reference-count":45,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"unspecified","delay-in-days":170,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains controversial, with conflicting evidence from landmark trials. We aimed to assess the impact of MRAs on mortality and cardiovascular outcomes post-acute MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase and Cochrane CENTRAL databases up to February 2025 for randomised controlled trials comparing MRAs with placebo or standard care in adults experiencing acute MI. Primary outcome was all-cause mortality; secondary outcomes included cardiovascular mortality, heart failure, recurrent MI and ventricular arrhythmia. Data were pooled using random-effects models, with heterogeneity explored via subgroup analyses and meta-regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>15 trials (n=18\u2009471) were included. MRA therapy demonstrated non-significant reductions in all-cause mortality (OR 0.80, 95%\u2009CI 0.55 to 1.18), cardiovascular mortality (OR 0.84, 95%\u2009CI 0.59 to 1.18), heart failure (OR 0.76, 95%\u2009CI 0.52 to 1.12), recurrent MI (OR 0.92, 95%\u2009CI 0.67 to 1.27) and ventricular arrhythmia (OR 0.83, 95%\u2009CI 0.47 to 1.47). Subgroup analyses revealed that trials with &gt;6 months follow-up demonstrated modest cardiovascular mortality reduction (OR 0.86, 95%\u2009CI 0.75 to 0.99). Effects were consistent across MRA types, left ventricular ejection fraction categories and initiation timing. Meta-regression showed no significant effect modifiers among baseline characteristics or concomitant therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In MI populations, MRA therapy did not significantly improve mortality or cardiovascular outcomes in the short term. However, a significant reduction in cardiovascular mortality emerged after 6 months, alongside a non-significant trend towards less heart failure, indicating potential benefits for high-risk patients with longer-term treatment rather than routine use in all acute MI cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003717","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T04:10:23Z","timestamp":1766117423000},"page":"e003717","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Mineralocorticoid receptor antagonists for acute myocardial infarction: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-9880","authenticated-orcid":false,"given":"Song Peng","family":"Ang","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of Arizona Medical Center - University Campus, Tucson, Arizona, USA"},{"name":"Internal Medicine, Rutgers The State University of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Ee","family":"Chia","sequence":"additional","affiliation":[{"name":"Internal Medicine, Texas Tech University Health Science Center, El Paso, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Bezerra","family":"Lima","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Iglesias","sequence":"additional","affiliation":[{"name":"Medicine, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunseuk","family":"Lee","sequence":"additional","affiliation":[{"name":"Internal Medicine, Rutgers The State University of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2514-8664","authenticated-orcid":false,"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[{"name":"HumanX, Delaware, Delaware, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Alam","sequence":"additional","affiliation":[{"name":"Cardiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-3694","authenticated-orcid":false,"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Internal Medicine, Texas Tech University Health Science Center, El Paso, Texas, USA"},{"name":"Cardiology, Texas Tech University Health Sciences Center, El Paso, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2025121820101739000_12.2.e003717.1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/eurjpc\/zwae019","article-title":"Unveiling the link between drinking patterns of alcohol and risk of major adverse cardiovascular events after acute coronary syndrome","volume":"31","author":"Chia","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025121820101739000_12.2.e003717.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"2025121820101739000_12.2.e003717.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001309"},{"key":"2025121820101739000_12.2.e003717.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000404"},{"key":"2025121820101739000_12.2.e003717.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.005"},{"key":"2025121820101739000_12.2.e003717.6","first-page":"202","article-title":"National Trends, Mortality and Outcomes in Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention in the United States","volume":"23","author":"Krittanawong","year":"2024","journal-title":"Crit Pathw Cardiol"},{"key":"2025121820101739000_12.2.e003717.7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11886-024-02163-x","article-title":"Coronary Intervention Outcomes in Patients with Liver Cirrhosis","volume":"27","author":"Ang","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"2025121820101739000_12.2.e003717.8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/eurheartj\/ehad811","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials","volume":"45","author":"Oraii","year":"2024","journal-title":"Eur Heart J"},{"key":"2025121820101739000_12.2.e003717.9","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20762"},{"key":"2025121820101739000_12.2.e003717.10","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011119003788"},{"key":"2025121820101739000_12.2.e003717.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"2025121820101739000_12.2.e003717.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"2025121820101739000_12.2.e003717.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.033"},{"key":"2025121820101739000_12.2.e003717.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu164"},{"key":"2025121820101739000_12.2.e003717.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405923"},{"key":"2025121820101739000_12.2.e003717.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025121820101739000_12.2.e003717.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"2025121820101739000_12.2.e003717.18","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025121820101739000_12.2.e003717.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025121820101739000_12.2.e003717.20","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121820101739000_12.2.e003717.21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","article-title":"Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial","volume":"211","author":"Bulluck","year":"2019","journal-title":"Am Heart J"},{"key":"2025121820101739000_12.2.e003717.22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5847\/wjem.j.issn.1920-8642.2013.01.009","article-title":"Effect of spironolactone on cardiac remodeling after acute myocardial infarction","volume":"4","author":"Wu","year":"2013","journal-title":"World J Emerg Med"},{"key":"2025121820101739000_12.2.e003717.23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjcard.2012.05.049","article-title":"Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone","volume":"110","author":"Kampourides","year":"2012","journal-title":"Am J Cardiol"},{"key":"2025121820101739000_12.2.e003717.24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCA.0b013e32833fd243","article-title":"The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study","volume":"21","author":"Kayrak","year":"2010","journal-title":"Coron Artery Dis"},{"key":"2025121820101739000_12.2.e003717.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfr129"},{"key":"2025121820101739000_12.2.e003717.26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/00365510902802278","article-title":"Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction","volume":"69","author":"Uzunhasan","year":"2009","journal-title":"Scand J Clin Lab Invest"},{"key":"2025121820101739000_12.2.e003717.27","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ahj.2005.03.032","article-title":"Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction","volume":"150","author":"Di Pasquale","year":"2005","journal-title":"Am Heart J"},{"key":"2025121820101739000_12.2.e003717.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068340.96506.0F"},{"key":"2025121820101739000_12.2.e003717.29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0167-5273(00)00425-3","article-title":"The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: safety and tolerability study","volume":"77","author":"Di Pasquale","year":"2001","journal-title":"Int J Cardiol"},{"key":"2025121820101739000_12.2.e003717.30","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.111258"},{"key":"2025121820101739000_12.2.e003717.31","first-page":"643","article-title":"Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study","volume":"125","author":"Rodr\u00edguez","year":"1997","journal-title":"Rev Med Chil"},{"key":"2025121820101739000_12.2.e003717.32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2018.0850","article-title":"Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis","volume":"178","author":"Dahal","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025121820101739000_12.2.e003717.33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2024.03.012","article-title":"Gender Differences in the Short and Long-Term Outcomes Following Rotational Atherectomy: A Meta-Analysis","volume":"219","author":"Ang","year":"2024","journal-title":"Am J Cardiol"},{"key":"2025121820101739000_12.2.e003717.34","first-page":"745","article-title":"Intravascular Imaging\u2010Guided Versus Angiography\u2010Guided Percutaneous Coronary Intervention in Patients With ST\u2010Segment Elevation Myocardial Infarction in the United States","volume":"105","author":"Krittanawong","year":"2025","journal-title":"Cathet Cardio Intervent"},{"key":"2025121820101739000_12.2.e003717.35","doi-asserted-by":"crossref","unstructured":"Ang SP , Chia JE , Misra K , et al . Autoimmune Rheumatic Diseases and Outcomes Following Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Angiol Open Access 2024. doi:10.1177\/00033197241255167","DOI":"10.1177\/00033197241255167"},{"key":"2025121820101739000_12.2.e003717.36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/HCO.0000000000001215","article-title":"Elevated C-reactive protein and cardiovascular risk","volume":"40","author":"Chia","year":"2025","journal-title":"Curr Opin Cardiol"},{"key":"2025121820101739000_12.2.e003717.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01116-0"},{"key":"2025121820101739000_12.2.e003717.38","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000289","article-title":"Mineralocorticoid receptor antagonists in cardiovascular translational biology","volume":"12","author":"Chilton","year":"2023","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"2025121820101739000_12.2.e003717.39","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.mayocp.2020.03.035","article-title":"Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure","volume":"95","author":"Secora","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2025121820101739000_12.2.e003717.40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cts.12702","article-title":"Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure","volume":"13","author":"Sarhan","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2025121820101739000_12.2.e003717.41","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/phar.2626","article-title":"NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial","volume":"41","author":"Dumeny","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2025121820101739000_12.2.e003717.42","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare11020253","article-title":"Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population","volume":"11","author":"Tran","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"2025121820101739000_12.2.e003717.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.062"},{"key":"2025121820101739000_12.2.e003717.44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000883","article-title":"Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy","volume":"3","author":"Bell","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2025121820101739000_12.2.e003717.45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCULATIONAHA.123.067620","article-title":"Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial","volume":"150","author":"Rajagopalan","year":"2024","journal-title":"Circulation"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T04:10:30Z","timestamp":1766117430000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/openhrt-2025-003717"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003717","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}